India got cheap Ozempic. No one knows how to sell it
Ozempic went off-patent in India this year, and everyone from Novo Nordisk to Nestlé has rushed in expecting a billion-dollar market. Instead, growth has already stalled, and the reason isn't price. It's culture. While Hollywood joked about Ozempic on late-night TV and Serena Williams advertised a GLP-1 program for a…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Daybreak
See all episodes →
Similar episodes from other shows
More like Daybreak →
Semaglutide Goes Generic: Big Pharma’s Moat Breaks
Can India break this Pharma Monopoly?
Can India become the pharmacy for weight-loss drugs?
#041 Prices of Expensive Diabetes Drugs Are Falling And More Manufacturers Are Rushing In
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.